Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Rhea-AI Summary

Dyne Therapeutics (NASDAQ:DYN), a clinical-stage biotech company focused on neuromuscular diseases, has successfully completed its previously announced public offering of common stock. The company sold 27,878,788 shares at $8.25 per share, including the full exercise of the underwriters' option to purchase additional shares.

The offering generated gross proceeds of approximately $230.0 million before deducting underwriting discounts, commissions, and offering expenses. Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities served as joint book-running managers, with Jones acting as co-manager for the offering.

Positive

• Raised significant capital of $230.0 million through the offering
• Full exercise of underwriters' option indicates strong demand
• Strengthened balance sheet to support clinical-stage pipeline development

Negative

• Potential dilution for existing shareholders due to issuance of 27.9 million new shares

News Market Reaction – DYN

-2.01%

-2.01% Session move

In the trading session that priced this news, DYN declined 2.01%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq:DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced underwritten public offering of 27,878,788 shares of its common stock at a public offering price of $8.25 per share, which includes 3,636,363 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $230.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Dyne. All of the shares in the offering were sold by Dyne.

Morgan Stanley, Jefferies, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Jones acted as co-manager for the offering.

The offering was made pursuant to a shelf registration statement on Form S-3 that was previously filed with the Securities and Exchange Commission (“SEC”) on March 5, 2024 and became automatically effective upon filing. The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering has been filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus may also be obtained by contacting: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.

Contacts:
 
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938

FAQ

How much money did Dyne Therapeutics (DYN) raise in its July 2025 public offering?

Dyne Therapeutics raised approximately $230.0 million in gross proceeds before deducting underwriting discounts, commissions, and offering expenses.

What was the share price for Dyne Therapeutics' public offering in July 2025?

The public offering price was $8.25 per share.

How many shares did Dyne Therapeutics sell in its July 2025 offering?

Dyne Therapeutics sold a total of 27,878,788 shares, which included 3,636,363 shares from the full exercise of the underwriters' option.

Who were the underwriters for Dyne Therapeutics' July 2025 public offering?

Morgan Stanley, Jefferies, Stifel, and Guggenheim Securities acted as joint book-running managers, with Jones as co-manager.

What is Dyne Therapeutics' main business focus?

Dyne Therapeutics is a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases.